NASH (nonalcoholic steatohepatitis, a form of liver disease), affects nearly 25% of the US population, and development of treatments for NASH is growing, even as scientists continue to uncover more about this chronic disease. Explore the outlook for NASH, and understand the factors that are driving research and development in the field, with a comprehensive overview from In Vivo that also explores the importance of partnerships and collaboration for the development of NASH treatments, as well as an update on late-stage trials for the disease.